A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Sponsor

Eli Lilly and Company (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT02857270

Collaborator

(none)

245

Enrollment

Locations

Arms

71.4

Anticipated Duration (Months)

18.8

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Condition or Disease	Intervention/Treatment	Phase
Advanced Cancer Metastatic Melanoma Metastatic Non-small Cell Lung Cancer Colorectal Cancer	Drug: LY3214996 Drug: Midazolam Drug: Abemaciclib Drug: Nab-paclitaxel Drug: Gemcitabine Drug: Encorafenib Drug: Cetuximab	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

245 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Actual Study Start Date :

Sep 29, 2016

Actual Primary Completion Date :

Feb 10, 2021

Anticipated Study Completion Date :

Sep 10, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: LY3214996 Dose Escalation LY3214996 given orally once a day (or twice a day) for 21 days.	Drug: LY3214996 Administered orally
Experimental: LY3214996 + Midazolam (Preliminary Drug-Drug Interactions [DDI]) LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days).	Drug: LY3214996 Administered orally Drug: Midazolam Administered orally
Experimental: LY3214996 Dose Expansion LY3214996 given orally (once a day) during each 21 day cycle.	Drug: LY3214996 Administered orally
Experimental: LY3214996 + Abemaciclib Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.	Drug: LY3214996 Administered orally Drug: Abemaciclib Administered orally Other Names: LY2835219
Experimental: LY3214996 + Nab-Paclitaxel + Gemcitabine Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.	Drug: LY3214996 Administered orally Drug: Nab-paclitaxel Administered IV Drug: Gemcitabine Administered IV
Experimental: LY3214996 + Encorafenib + Cetuximab Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.	Drug: LY3214996 Administered orally Drug: Encorafenib Administered orally Drug: Cetuximab Administered IV
Experimental: Japan Part 1 LY3214996 given orally.	Drug: LY3214996 Administered orally
Experimental: Japan Part 2 LY3214996 given orally and abemaciclib given orally.	Drug: LY3214996 Administered orally Drug: Abemaciclib Administered orally Other Names: LY2835219

Outcome Measures

Primary Outcome Measures

Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs) [Cycle 1 (21 Days)]

Secondary Outcome Measures

Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of LY3214996 Administered as Monotherapy and when Administered in Combination with Nab-Paclitaxel Plus Gemcitabine, Abemaciclib and Encorafenib Plus Cetuximab [Cycle 1 Day 1 through Cycle 2 Day 1 (up to 28 Day Cycles)]
PK: AUC of Gemcitabine when Administered with LY3214996 [Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)]
PK: AUC of Nab-Paclitaxel when Administered with LY3214996 [Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)]
PK: AUC of Abemaciclib and its Metabolites when Administered with LY3214996 [Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)]
PK: AUC of Encorafenib when Administered with LY3214996 [Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)]
PK: AUC of Cetuximab when Administered with LY3214996 [Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)]
PK: AUC of Midazolam and its 1'-Hydroxymidazolam Metabolite when Administered Alone and in Combination with LY3214996 [Cycle 1 Day 1 through Cycle 1 Day 16 (21 Day Cycles)]
Objective Response Rate (ORR): Percentage of Participants With a Complete (CR) or Partial Response (PR) [Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Estimated up to 6 Months)]
Duration of Response (DoR) [Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)]
Time to First Response (TTR) [Baseline to Date of CR or PR (Estimated up to 6 Months)]
Progression Free Survival (PFS) [Baseline to Progressive Disease or Death of Any Cause (Estimated up to 12 Months)]
Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR [Baseline through Measured Progressive Disease (Estimated up to 6 Months)]
Overall Survival (OS) (Dose Expansion Arms Only) [Baseline to Date of Death from Any Cause (Estimated up to 2 Years)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Have advanced or metastatic cancer (solid tumors) and be an appropriate candidate for experimental therapy.
Part B (No Longer Enrolling Participants): Have advanced or metastatic cancer with an activating mitogen-activated protein kinase pathway alteration, BRAF mutant metastatic melanoma refractory to or relapsed after treatment with RAF and/or MEK inhibitors, metastatic melanoma with a NRAS mutation, or BRAF mutant NSCLC.
Part C: Advanced, unresectable cancer (dose escalation) and advanced, unresectable, or metastatic non-small cell lung cancer with a BRAF or RAS mutation, or NRAS mutant melanoma (dose expansion).
Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal adenocarcinoma (dose escalation and dose expansion).
Part E: Metastatic BRAF V600E colorectal cancer.
Have discontinued previous treatments for cancer and have resolution, except where otherwise stated in the inclusion criteria, of all clinically significant toxic effects of prior chemotherapy, surgery, or radiotherapy to Grade ≤1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
Have adequate organ function.
Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.

Exclusion Criteria:

Have serious preexisting medical conditions.
Have a known human immunodeficiency virus (HIV) infection or known activated/reactivated hepatitis A, B, or C.
Have symptomatic central nervous system malignancy or metastasis.
Have current hematologic malignancies, acute or chronic leukemia.
Have a second primary malignancy that in the judgment of the investigator or Lilly may affect the interpretation of results.
Have prior malignancies. Participants with carcinoma in situ of any origin and participants with prior malignancies who are in remission and whose likelihood of recurrence is very low, as judged by the Lilly clinical research physician, are eligible for this study.
Have a mean QT interval corrected for heart rate (QTc) of ≥470 milliseconds on screening electrocardiogram (ECG) as calculated using the Bazett's formula at several consecutive days of assessment.
Have participated, within the last 28 days in a clinical trial involving an investigational product or are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor.
If female, is pregnant, breastfeeding, or planning to become pregnant.
Have history or findings of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study.
Currently using concomitant medications that are strong inhibitors or inducers of CYP3A4.
Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy.
Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Georgetown University Medical Center	Washington	District of Columbia	United States	20007
2	Florida Cancer Specialists	Sarasota	Florida	United States	34232
3	Massachusetts General Hospital	Boston	Massachusetts	United States	02114
4	Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	United States	03756-0001
5	UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	United States	15232-1305
6	Sarah Cannon Cancer Center	Nashville	Tennessee	United States	37203
7	Tennessee Oncology PLLC	Nashville	Tennessee	United States	37203
8	University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030
9	St Vincent's Hospital	Sydney	New South Wales	Australia	2010
10	Linear Clinical Research Ltd	Nedlands	Western Australia	Australia	6009
11	Gustave Roussy	Villejuif Cedex		France	94805
12	Shizuoka Cancer Center	Sunto-Gun	Shizuoka	Japan	411-8777
13	National Cancer Center Hospital	Chuo-ku	Tokyo	Japan	104-0045

Sponsors and Collaborators

Eli Lilly and Company

Investigators

Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company